Can NT-proBNP guided therapy during hospital admission for acutely decompensated heart failure reduce mortality and readmissions?

Completed

• Conditions: Acutely decompensated heart failureAcute heart failureAcuut hartfalenAcuut gedecompenseerd hartfalen

• Registration Number: NL-OMON21346
• Lead Sponsor: Academical Medical Center - University of Amsterdam

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

1. Hospital admission because of clinically validated acutely decompensated heart failure. A clinical diagnosis of HF is made on the basis of a HF-score of 2 points or higher;

2.Elevated NT-proBNP levels ≥1700 ng/L (≥200 pmol/L) on hospital admission;

Exclusion Criteria

1. Severe Chronic Obstructive Pulmonary Disease (COPD) with FEV<1l/min;

2. Pulmonary embolism within 1 month prior to admission and pulmonary hypertension not caused by left ventricle dysfunction (LVD);

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Readmissions and mortality in the first 180 days;<br /><br>2. The number of days alive out of hospital in the first 180 days.

Secondary Outcome Measures

Name	Time	Method
1. Readmissions in the first 180 days;<br /><br>2. Mortality in the first 180 days;<br /><br>3. Cost effectiveness in terms of hospitalization days in the first 180 days;<br /><br>4. Readmissions and mortality in the first 90 days.